{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:16:24Z","timestamp":1793042184302,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some cutaneous T-cell lymphomas. The antibody\u2013drug conjugate brentuximab vedotin targets CD30-positive cells and has been evaluated for the treatment of various lymphoma entities. This narrative review summarizes 10\u00a0years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types. The collective body of evidence for brentuximab vedotin demonstrates that exploitation of CD30 can provide sustained benefits across a range of different CD30-positive lymphomas, in both clinical trials and real-world settings. Preliminary experience with brentuximab vedotin in combination with immune checkpoint inhibitors for relapsed\/refractory cHL is encouraging, but further exploration is required. The optimal use of brentuximab vedotin for first-line therapy of PTCL remains to be determined. Further research is required on brentuximab vedotin treatment in high-risk patient populations, and in rare lymphoma subtypes, for which no standard of care exists. Novel therapies targeting CD30 include chimeric antigen receptor therapies and bispecific antibody T-cell engagers, which may be expected to further improve outcomes for patients with CD30-positive lymphomas in the coming years.<\/jats:p>","DOI":"10.1007\/s00277-022-05054-9","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T08:03:04Z","timestamp":1670918584000},"page":"13-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Anti-CD30 antibody\u2013drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives"],"prefix":"10.1007","volume":"102","author":[{"given":"H. Miles","family":"Prince","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"9","key":"5054_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"CA van der Weyden","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J 7(9):e603. https:\/\/doi.org\/10.1038\/bcj.2017.85","journal-title":"Blood Cancer J"},{"issue":"8","key":"5054_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","volume":"14","author":"K Karube","year":"2021","unstructured":"Karube K, Kakimoto Y, Tonozuka Y, Ohshima K (2021) The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol 14(8):777\u2013787. https:\/\/doi.org\/10.1080\/17474086.2021.1955344","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"5054_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/cup.13894","volume":"48","author":"F Kampa","year":"2021","unstructured":"Kampa F, Mitteldorf C (2021) A review of CD30 expression in cutaneous neoplasms. J Cutan Pathol 48(4):495\u2013510. https:\/\/doi.org\/10.1111\/cup.13894","journal-title":"J Cutan Pathol"},{"issue":"6","key":"5054_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/jop.13208","volume":"50","author":"CI Rodrigues-Fernandes","year":"2021","unstructured":"Rodrigues-Fernandes CI, Abreu LG, Radhakrishnan R, Perez D, Amaral-Silva GK, Gondak RO, Rahimi S, Brennan PA, Fonseca FP, Vargas PA (2021) Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: a systematic review with meta-analysis. J Oral Pathol Med 50(6):587\u2013593. https:\/\/doi.org\/10.1111\/jop.13208","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"5054_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17474086.2019.1558399","volume":"12","author":"C Van Der Weyden","year":"2019","unstructured":"Van Der Weyden C, Dickinson M, Whisstock J, Prince HM (2019) Brentuximab vedotin in T-cell lymphoma. Expert Rev Hematol 12(1):5\u201319. https:\/\/doi.org\/10.1080\/17474086.2019.1558399","journal-title":"Expert Rev Hematol"},{"key":"5054_CR6","unstructured":"Seattle Genetics (2018) ADCETRIS prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125388s097lbl.pdf. Accessed 19 December 2022."},{"key":"5054_CR7","unstructured":"Takeda Pharma A\/S (2021) ADCETRIS summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcetris-epar-product-information_en.pdf. Accessed 19 December 2022."},{"issue":"12","key":"5054_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP (2017) Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117(12):1736\u20131742. https:\/\/doi.org\/10.1038\/bjc.2017.367","journal-title":"Br J Cancer"},{"key":"5054_CR9","unstructured":"National Comprehensive Cancer Network (NCCN) Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hodgkin Lymphoma. V.2.2022. \u00a9National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 19, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org . NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"5054_CR10","doi-asserted-by":"publisher","unstructured":"Eichenauer DA, Aleman BMP, Andre M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M, ESMO Guidelines Committee (2018) Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 (Suppl 4):iv19\u2013iv29. https:\/\/doi.org\/10.1093\/annonc\/mdy080","DOI":"10.1093\/annonc\/mdy080"},{"key":"5054_CR11","unstructured":"National Comprehensive Cancer Network (NCCN) Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Pediatric Hodgkin Lymphoma. V.3.2021. \u00a9National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 18, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org . NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"4","key":"5054_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, Group E-S","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, Group E-S (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378(4):331\u2013344. https:\/\/doi.org\/10.1056\/NEJMoa1708984","journal-title":"N Engl J Med"},{"issue":"6","key":"5054_CR13","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","volume":"8","author":"DJ Straus","year":"2021","unstructured":"Straus DJ, Dlugosz-Danecka M, Connors JM, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J (2021) Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 8(6):e410\u2013e421. https:\/\/doi.org\/10.1016\/S2352-3026(21)00102-2","journal-title":"Lancet Haematol"},{"issue":"13","key":"5054_CR14","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","volume":"35","author":"PJ Brockelmann","year":"2017","unstructured":"Brockelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, Meissner J, Kerkhoff A, Ludwig WD, Fuchs M, Borchmann P, Engert A (2017) Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin study group HD7 to HD12 trials. J Clin Oncol 35(13):1444\u20131450. https:\/\/doi.org\/10.1200\/JCO.2016.71.3289","journal-title":"J Clin Oncol"},{"issue":"4","key":"5054_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, D\u0142ugosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ (2022) Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 387(4):310\u2013320. https:\/\/doi.org\/10.1056\/NEJMoa2206125","journal-title":"N Engl J Med"},{"issue":"12","key":"5054_CR16","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1080\/10428194.2020.1791846","volume":"61","author":"D Straus","year":"2020","unstructured":"Straus D, Collins G, Walewski J, Zinzani PL, Grigg A, Sureda A, Illes A, Kim TM, Alekseev S, Specht L, Buccheri V, Younes A, Connors J, Forero-Torres A, Fenton K, Gautam A, Purevjal I, Liu R, Gallamini A (2020) Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III\/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma 61(12):2931\u20132938. https:\/\/doi.org\/10.1080\/10428194.2020.1791846","journal-title":"Leuk Lymphoma"},{"key":"5054_CR17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278438","author":"AM Evens","year":"2021","unstructured":"Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A (2021) Older patients (aged >\/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2021.278438","journal-title":"Haematologica"},{"issue":"2","key":"5054_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hon.2838","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Radford J, Ansell SM, Illes A, Sureda A, Connors JM, Sykorova A, Shibayama H, Abramson JS, Chua NS, Friedberg JW, Koren J, LaCasce AS, Molina L, Engley G, Fenton K, Jolin H, Liu R, Gautam A, Gallamini A (2021) Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol 39(2):185\u2013195. https:\/\/doi.org\/10.1002\/hon.2838","journal-title":"Hematol Oncol"},{"key":"5054_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01386-z","author":"C Damaschin","year":"2021","unstructured":"Damaschin C, Goergen H, Kreissl S, Plutschow A, Breywisch F, Mathas S, Meissner J, Sokler M, Topp MS, Vucinic V, Zimmermann A, von Tresckow B, Fuchs M, Engert A, Borchmann P, Eichenauer DA (2021) Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. Leukemia. https:\/\/doi.org\/10.1038\/s41375-021-01386-z","journal-title":"Leukemia"},{"issue":"12","key":"5054_CR20","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","volume":"18","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P (2017) Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol 18(12):1680\u20131687. https:\/\/doi.org\/10.1016\/S1470-2045(17)30696-4","journal-title":"Lancet Oncol"},{"key":"5054_CR21","unstructured":"ClinicalTrials.gov NCT02661503: HD21 for advanced stages. University of Cologne. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02661503. Accessed 19 December 2022."},{"key":"5054_CR22","unstructured":"ClinicalTrials.gov NCT03517137: Very early PET-response adapted targeted therapy for advanced Hodgkin Lymphoma: A single -arm phase II study (COBRA). European Organisation for Research and Treatment of Cancer (EORTC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03517137. Accessed 19 December 2022."},{"issue":"1","key":"5054_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjh.17073","volume":"193","author":"A Gibb","year":"2021","unstructured":"Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, Collins GP, Menne T, McKay P, Fields PA, Miall FM, Nagy E, Wheatley K, Reed R, Baricevic-Jones I, Barrington S, Radford J (2021) Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). Br J Haematol 193(1):63\u201371. https:\/\/doi.org\/10.1111\/bjh.17073","journal-title":"Br J Haematol"},{"issue":"30","key":"5054_CR24","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/jco.2018.79.0139","volume":"36","author":"AM Evens","year":"2018","unstructured":"Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA (2018) Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 36(30):3015\u20133022. https:\/\/doi.org\/10.1200\/jco.2018.79.0139","journal-title":"J Clin Oncol"},{"issue":"11","key":"5054_CR25","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","volume":"4","author":"SI Park","year":"2020","unstructured":"Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, Deal AM, Noe JF, Ansell SM (2020) ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv 4(11):2548\u20132555. https:\/\/doi.org\/10.1182\/bloodadvances.2020001871","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"5054_CR26","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1182\/blood.V130.Suppl_1.736.736","volume":"130","author":"L-M Fornecker","year":"2017","unstructured":"Fornecker L-M, Lazarovici J, Aurer I, Casasnovas R-O, Gac A-C, Bonnet C, Bouabdallah K, Perrot A, Specht L, Touati M, Eisenmann JC, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Bellei M, traverse-Glehen A, Copie C, Hutchings M, Versari A, Meignan M, Federico M, Andre M, (2017) PET-based response after 2 cycles of brentuximab vedotin in combination with AVD for first-line treatment of unfavorable early-stage Hodgkin lymphoma: first analysis of the primary endpoint of breach, a randomized phase II trial of Lysa-FIL-EORTC Intergroup. Blood 130(Supplement 1):736\u2013736. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.736.736","journal-title":"Blood"},{"issue":"20","key":"5054_CR27","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO.20.03286","volume":"39","author":"ML Metzger","year":"2021","unstructured":"Metzger ML, Link MP, Billett AL, Flerlage J, Lucas JT Jr, Mandrell BN, Ehrhardt MJ, Bhakta N, Yock TI, Friedmann AM, de Alarcon P, Luna-Fineman S, Larsen E, Kaste SC, Shulkin B, Lu Z, Li C, Hiniker SM, Donaldson SS, Hudson MM, Krasin MJ (2021) Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation. J Clin Oncol 39(20):2276\u20132283. https:\/\/doi.org\/10.1200\/JCO.20.03286","journal-title":"J Clin Oncol"},{"key":"5054_CR28","doi-asserted-by":"publisher","unstructured":"Franklin ARK, Luisi FAV, Pianovski MA, Salvino MA, Fagioli F, Epelman S, B De Abreu Lima L, Norris RE, Odone-Filho V, Zecca M, Favre C, Kobayashi R, Sidi Y, Campana F, Leonard EJ, Locatelli F (2021) An open-label, phase 1\/2 study of frontline brentuximab vedotin + adriamycin, vinblastine, and dacarbazine in paediatric patients with advanced stage Hodgkin lymphoma. Hematological Oncology 39(S2). doi: https:\/\/doi.org\/10.1002\/hon.37_2879","DOI":"10.1002\/hon.37_2879"},{"issue":"18","key":"5054_CR29","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189. https:\/\/doi.org\/10.1200\/JCO.2011.38.0410","journal-title":"J Clin Oncol"},{"issue":"7","key":"5054_CR30","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.26355\/eurrev_202104_25547","volume":"25","author":"Z Wang","year":"2021","unstructured":"Wang Z, Sun K, Zhu ZM, Zhang P, Yang J, Yang SW, Zheng MQ (2021) Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 25(7):2941\u20132948. https:\/\/doi.org\/10.26355\/eurrev_202104_25547","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"5054_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1634\/theoncologist.2014-0420","volume":"20","author":"C Carlo-Stella","year":"2015","unstructured":"Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A (2015) Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist 20(3):323\u2013328. https:\/\/doi.org\/10.1634\/theoncologist.2014-0420","journal-title":"Oncologist"},{"key":"5054_CR32","unstructured":"Beynarovich A, Borzenkova E, Lepik K, Mikhailova N, Kozlov A, Zalyalov Y, Lepik E, Alyanskiy A, Pirogova O, Darskaya E, Moiseev I, Afanasyev B Brentuximab vedotin therapy in patients with relapsed or refractory classical Hodgkin lymphoma after allogeneic stem cells transplantation: single center experience (abstract EP1155). In: European Hematology Association (EHA), Virtual, 2020."},{"issue":"10","key":"5054_CR33","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bmt.2016.129","volume":"51","author":"P Tsirigotis","year":"2016","unstructured":"Tsirigotis P, Danylesko I, Gkirkas K, Shem-Tov N, Yerushalmi R, Stamouli M, Avigdor A, Spyridonidis A, Gauthier J, Goldstein G, Apostolidis J, Mohty M, Shimoni A, Nagler A (2016) Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 51(10):1313\u20131317. https:\/\/doi.org\/10.1038\/bmt.2016.129","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5054_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/annonc\/mdx791","volume":"29","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29(3):724\u2013730. https:\/\/doi.org\/10.1093\/annonc\/mdx791","journal-title":"Ann Oncol"},{"issue":"5","key":"5054_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/imj.13415","volume":"47","author":"H Mediwake","year":"2017","unstructured":"Mediwake H, Morris K, Curley C, Butler J, Kennedy G (2017) Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed\/refractory CD30 positive lympho-proliferative disorders: a single centre experience. Intern Med J 47(5):574\u2013578. https:\/\/doi.org\/10.1111\/imj.13415","journal-title":"Intern Med J"},{"issue":"3","key":"5054_CR36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3109\/10428194.2014.930852","volume":"56","author":"T Illidge","year":"2015","unstructured":"Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, Advani R (2015) Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma 56(3):703\u2013710. https:\/\/doi.org\/10.3109\/10428194.2014.930852","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5054_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.15152","volume":"181","author":"A Bazarbachi","year":"2018","unstructured":"Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A (2018) Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol 181(1):86\u201396. https:\/\/doi.org\/10.1111\/bjh.15152","journal-title":"Br J Haematol"},{"issue":"8","key":"5054_CR38","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","volume":"8","author":"RC Lynch","year":"2021","unstructured":"Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, Libby EN 3rd, Philip M, Coye H, Martino CN, Bhark SL, Morris K, Rasmussen H, Behnia S, Voutsinas J, Gopal AK (2021) Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study. Lancet Haematol 8(8):e562\u2013e571. https:\/\/doi.org\/10.1016\/S2352-3026(21)00170-8","journal-title":"Lancet Haematol"},{"issue":"4","key":"5054_CR39","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","volume":"106","author":"MJ Kersten","year":"2021","unstructured":"Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A (2021) Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study. Haematologica 106(4):1129\u20131137. https:\/\/doi.org\/10.3324\/haematol.2019.243238","journal-title":"Haematologica"},{"issue":"4","key":"5054_CR40","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C (2019) Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol 30(4):612\u2013620. https:\/\/doi.org\/10.1093\/annonc\/mdz009","journal-title":"Ann Oncol"},{"issue":"1","key":"5054_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O\u2019Connor OA, Josephson N, Wang Y, Advani R (2018) Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132(1):40\u201348. https:\/\/doi.org\/10.1182\/blood-2017-11-815183","journal-title":"Blood"},{"issue":"1","key":"5054_CR42","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1186\/s12885-020-07561-2","volume":"20","author":"A Sureda","year":"2020","unstructured":"Sureda A, Andre M, Borchmann P, da Silva MG, Gisselbrecht C, Vassilakopoulos TP, Zinzani PL, Walewski J (2020) Improving outcomes after autologous transplantation in relapsed\/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer 20(1):1088. https:\/\/doi.org\/10.1186\/s12885-020-07561-2","journal-title":"BMC Cancer"},{"issue":"1","key":"5054_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/asheducation-2018.1.213","volume":"2018","author":"AF Herrera","year":"2018","unstructured":"Herrera AF (2018) Where does PD-1 blockade fit in HL therapy? Hematology Am Soc Hematol Educ Program 2018(1):213\u2013220. https:\/\/doi.org\/10.1182\/asheducation-2018.1.213","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5054_CR44","doi-asserted-by":"publisher","unstructured":"Gardai SJ, Epp A, Law C-L (2015) Brentuximab vedotin-mediated immunogenic cell death. Cancer Research 75 (15 Suppl):Abstract 2469. doi: https:\/\/doi.org\/10.1158\/1538-7445.AM2015-2469","DOI":"10.1158\/1538-7445.AM2015-2469"},{"key":"5054_CR45","doi-asserted-by":"publisher","unstructured":"Cao AT, Law C-L, Gardai SJ, Heiser RA (2017) Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo. Cancer Research 77(13 Suppl):Abstract 5588. doi: https:\/\/doi.org\/10.1158\/1538-7445.AM2017-5588","DOI":"10.1158\/1538-7445.AM2017-5588"},{"issue":"8","key":"5054_CR46","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P Muller","year":"2014","unstructured":"Muller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A (2014) Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2(8):741\u2013755. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0198","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"5054_CR47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF (2021) Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 138(6):427\u2013438. https:\/\/doi.org\/10.1182\/blood.2020009178","journal-title":"Blood"},{"issue":"9","key":"5054_CR48","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","volume":"7","author":"CS Diefenbach","year":"2020","unstructured":"Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM (2020) Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial. Lancet Haematol 7(9):e660\u2013e670. https:\/\/doi.org\/10.1016\/S2352-3026(20)30221-0","journal-title":"Lancet Haematol"},{"issue":"1\u20132","key":"5054_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14740\/jh596","volume":"9","author":"TY Yu","year":"2020","unstructured":"Yu TY, Dai MS (2020) Prolonged remission by pembrolizumab and brentuximab-vedotin combination therapy in heavily-pretreated relapsed\/refractory Hodgkin\u2019s lymphoma. J Hematol 9(1\u20132):30\u201332. https:\/\/doi.org\/10.14740\/jh596","journal-title":"J Hematol"},{"issue":"4","key":"5054_CR50","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL, investigators K-, (2021) Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 22(4):512\u2013524. https:\/\/doi.org\/10.1016\/S1470-2045(21)00005-X","journal-title":"Lancet Oncol"},{"issue":"9980","key":"5054_CR51","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J, Group AS","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J, Group AS (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853\u20131862. https:\/\/doi.org\/10.1016\/S0140-6736(15)60165-9","journal-title":"Lancet"},{"issue":"25","key":"5054_CR52","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J (2018) Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132(25):2639\u20132642. https:\/\/doi.org\/10.1182\/blood-2018-07-861641","journal-title":"Blood"},{"issue":"1","key":"5054_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2939","volume":"40","author":"F Massaro","year":"2022","unstructured":"Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C, Cantonetti M, Visentin A, Scalzulli PR, Rossi A, Galimberti S, Cimminiello M, Gini G, Musso M, Sorio M, Arcari A, Zilioli VR, Luppi M, Mannina D, Fabbri A, Pietrantuono G, Annibali O, Tafuri A, Prete E, Mule A, Barbolini E, Marcheselli L, Luminari S, Merli F (2022) Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Hematol Oncol 40(1):31\u201339. https:\/\/doi.org\/10.1002\/hon.2939","journal-title":"Hematol Oncol"},{"key":"5054_CR54","doi-asserted-by":"crossref","unstructured":"Chung S, White J, Toze CL, Sutherland HJ, Sanford D, Anula Rodrigo J, Nevill TJ, Narayanan S, Nantel SH, Kuchenbauer F, Hay KA, Forrest DL, Abou Mourad Y, Song K, Power M (2021) Autologous stem cell transplant outcome in classic Hodgkin lymphoma patients in the era of post-transplant brentuximab vedotin consolidation (abstract #3935). Paper presented at the American Society of Hematology (ASH), Georgia, Atlanta, 11\u201314 December","DOI":"10.1182\/blood-2021-154492"},{"key":"5054_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-138666","volume":"136","author":"A Marouf","year":"2020","unstructured":"Marouf A, Cottereau AS, Fouquet G, Kanoun S, Franchi P, Ricci R, Meignan M, Sibon D, Gastinne T, Borel C, Hammoud M, Sicard G, Gille R, Cavalieri D, Stamatoulas Bastard A, Clement-Filliatre L, Lazarovici J, Chauchet A, Fornecker LM, Amorin S, Roquet M, Raus N, Casasnovas R-O, Cartron G, Ghesquieres H, Brice P, Hermine O, Bouscary D, Rubio MT, Tamburini J, Deau Fischer B (2020) Amahrelis: Adcetris maintenance after autologous stem cell transplantation in Hodgkin lymphoma: a real life study from Sfgmtc and Lysa groups. Blood 136:20\u201321. https:\/\/doi.org\/10.1182\/blood-2020-138666","journal-title":"Blood"},{"issue":"4","key":"5054_CR56","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/hon.2897","volume":"39","author":"OM Akay","year":"2021","unstructured":"Akay OM, Ozbalak M, Pehlivan M, Yildiz B, Uzay A, Yigenoglu TN, Elverdi T, Kaynar L, Ayyildiz O, Yonal Hindilerden I, Goksoy HS, Izmir Guner S, Gunes AK, Sonmez M, Kurt Yuksel M, Civriz Bozdag S, Ozkurt ZN, Toptas T, Dogu MH, Salim O, Saydam G, Yavasoglu I, Ayli M, Ozet G, Albayrak M, Birtas Atesoglu E, Toprak SK, Yildirim R, Mehtap O, Kalayoglu Besisik S, Nalcaci M, Altuntas F, Ferhanoglu B (2021) Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: multicenter retrospective study. Hematol Oncol 39(4):498\u2013505. https:\/\/doi.org\/10.1002\/hon.2897","journal-title":"Hematol Oncol"},{"key":"5054_CR57","doi-asserted-by":"crossref","unstructured":"Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov I, Cuglievan B, Dave H, Deyell RJ, Flerlage J, Franklin A, Krajewski J, Leger KJ, Marks L, Norris R, Pacheco M, Willen F, Yan AP, Harker-Murray P, Giulino Roth L (2021) Brentuximab vedotin as consolidation therapy following autologous stem cell transplantation in children and adolescents with relapsed\/refractory Hodgkin lymphoma: a multi-center retrospective analysis (abstract #2465). Paper presented at the American Society of Hematology (ASH), Georgia, Atlanta, 11\u201314 December","DOI":"10.1182\/blood-2021-151808"},{"issue":"3","key":"5054_CR58","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12185-020-03039-w","volume":"113","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M (2021) Safety profile of brentuximab vedotin in Japanese patients with relapsed\/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. Int J Hematol 113(3):404\u2013412. https:\/\/doi.org\/10.1007\/s12185-020-03039-w","journal-title":"Int J Hematol"},{"issue":"21","key":"5054_CR59","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.7150\/jca.29308","volume":"10","author":"Z Kral","year":"2019","unstructured":"Kral Z, Michalka J, Mocikova H, Markova J, Sykorova A, Belada D, Jungova A, Vokurka S, Lukasova M, Prochazka V, Duras J, Hajek R, Dusek L, Drgona L, Ladicka M, Ballova V, Vranovsky A (2019) Treatment of relapsed\/Refractory Hodgkin lymphoma: real-world data from the Czech Republic and Slovakia. J Cancer 10(21):5041\u20135048. https:\/\/doi.org\/10.7150\/jca.29308","journal-title":"J Cancer"},{"issue":"10","key":"5054_CR60","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00277-020-04204-1","volume":"99","author":"LI Pinczes","year":"2020","unstructured":"Pinczes LI, Szabo R, Illes A, Foldeak D, Piukovics K, Szomor A, Gopcsa L, Miltenyi Z (2020) Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma. Ann Hematol 99(10):2385\u20132392. https:\/\/doi.org\/10.1007\/s00277-020-04204-1","journal-title":"Ann Hematol"},{"issue":"3","key":"5054_CR61","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1111\/bjh.17274","volume":"192","author":"A McMillan","year":"2021","unstructured":"McMillan A, O\u2019Neill AT, Townsend W, Lambert J, Virchis A, Shah R, Menezes L, Humphries P, Von Both K, Grandage V, Carpenter B, Hough R, Ardeshna KM, Daw S (2021) The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series. Br J Haematol 192(3):e84\u2013e87. https:\/\/doi.org\/10.1111\/bjh.17274","journal-title":"Br J Haematol"},{"issue":"3","key":"5054_CR62","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/1120009X.2021.1976912","volume":"34","author":"B Uncu Ulu","year":"2022","unstructured":"Uncu Ulu B, Dal MS, Yonal Hindilerden I, Akay OM, Mehtap O, Buyukkurt N, Hindilerden F, Gunes AK, Yigenoglu TN, Basci S, Kizil Cakar M, Yanardag Acik D, Korkmaz S, Ulas T, Ozet G, Ferhanoglu B, Nalcaci M, Altuntas F (2022) Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. J Chemother 34(3):190\u2013198. https:\/\/doi.org\/10.1080\/1120009X.2021.1976912","journal-title":"J Chemother"},{"issue":"1","key":"5054_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-020-00603-3","volume":"16","author":"T Othman","year":"2021","unstructured":"Othman T, Herrera A, Mei M (2021) Emerging therapies in relapsed and refractory Hodgkin lymphoma: what comes next after brentuximab vedotin and PD-1 inhibition? Curr Hematol Malig Rep 16(1):1\u20137. https:\/\/doi.org\/10.1007\/s11899-020-00603-3","journal-title":"Curr Hematol Malig Rep"},{"key":"5054_CR64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","volume":"7","author":"NL Bartlett","year":"2014","unstructured":"Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A (2014) Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7:24. https:\/\/doi.org\/10.1186\/1756-8722-7-24","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5054_CR65","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/10428194.2019.1654100","volume":"61","author":"N Fukuhara","year":"2020","unstructured":"Fukuhara N, Yamamoto G, Tsujimura H, Chou T, Shibayama H, Yanai T, Shibuya K, Izutsu K (2020) Retreatment with brentuximab vedotin in patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma 61(1):176\u2013180. https:\/\/doi.org\/10.1080\/10428194.2019.1654100","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"5054_CR66","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B (2017) Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 127(9):3462\u20133471. https:\/\/doi.org\/10.1172\/JCI94306","journal-title":"J Clin Invest"},{"issue":"32","key":"5054_CR67","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B (2020) Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 38(32):3794\u20133804. https:\/\/doi.org\/10.1200\/JCO.20.01342","journal-title":"J Clin Oncol"},{"key":"5054_CR68","doi-asserted-by":"publisher","unstructured":"Ahmed S, Flinn IW, Mei M, Riedell PA, Armand P, Grover NS, Engert A, Lapteva N, Nadler PI, Myo A, Heslop HE (2021) Safety and Efficacy Profile of Autologous CD30. CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial). Blood 138:3847. https:\/\/doi.org\/10.1182\/blood-2021-146100","DOI":"10.1182\/blood-2021-146100"},{"key":"5054_CR69","unstructured":"ClinicalTrials.gov NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed\/Refractory Hodgkin Lymphoma (CHARIOT). Tessa Therapeutics. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04268706. Accessed 14 July 2022."},{"key":"5054_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.607362","volume":"10","author":"Y Xue","year":"2020","unstructured":"Xue Y, Lai X, Li R, Ge C, Zeng B, Li Z, Fu Q, Zhao L, Dong S, Yang J, Guo J, Meng Q, Tan Q, Li Z, Ding H, Zhang Y, Liu S, Chang AH, Yao H, Luo R (2020) CD19 and CD30 CAR T-cell immunotherapy for high-risk classical Hodgkin\u2019s lymphoma. Front Oncol 10:607362. https:\/\/doi.org\/10.3389\/fonc.2020.607362","journal-title":"Front Oncol"},{"issue":"26","key":"5054_CR71","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A (2015) A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125(26):4024\u20134031. https:\/\/doi.org\/10.1182\/blood-2014-12-614636","journal-title":"Blood"},{"issue":"21","key":"5054_CR72","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2019004701","volume":"136","author":"NL Bartlett","year":"2020","unstructured":"Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM (2020) A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 136(21):2401\u20132409. https:\/\/doi.org\/10.1182\/blood.2019004701","journal-title":"Blood"},{"issue":"8","key":"5054_CR73","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","volume":"63","author":"S Sasse","year":"2022","unstructured":"Sasse S, Br\u00f6ckelmann PJ, Momotow J, Pl\u00fctschow A, H\u00fcttmann A, Basara N, Koenecke C, Martin S, Bentz M, Grosse-Thie C, Thorspecken S, de Wit M, Kobe C, Dietlein M, Tresckow BV, Fuchs M, Borchmann P, Engert A (2022) AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leuk Lymphoma 63(8):1871\u20131878. https:\/\/doi.org\/10.1080\/10428194.2022.2095623","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"5054_CR74","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","volume":"27","author":"LN Kerbauy","year":"2021","unstructured":"Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K (2021) Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) malignancies. Clin Cancer Res 27(13):3744\u20133756. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0164","journal-title":"Clin Cancer Res"},{"key":"5054_CR75","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3389\/fonc.2019.00945","volume":"9","author":"S Rajendran","year":"2019","unstructured":"Rajendran S, Li Y, Ngoh E, Wong HY, Cheng MS, Wang CI, Schwarz H (2019) Development of a bispecific antibody targeting CD30 and CD137 on Hodgkin and Reed-Sternberg cells. Front Oncol 9:945. https:\/\/doi.org\/10.3389\/fonc.2019.00945","journal-title":"Front Oncol"},{"issue":"28","key":"5054_CR76","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","volume":"39","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Shah G, Schoder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH (2021) Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 39(28):3109\u20133117. https:\/\/doi.org\/10.1200\/JCO.21.01056","journal-title":"J Clin Oncol"},{"key":"5054_CR77","doi-asserted-by":"crossref","unstructured":"Herrera AF, Li H, Castellino SM, Rutherford SC, Davison K, Evans AG, Punnett A, al e SWOG S1826: a phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma. In: 62nd ASH Annual Meeing, Virtual meeting, 5\u20138 December 2020.","DOI":"10.1182\/blood-2020-136422"},{"issue":"3","key":"5054_CR78","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Ill\u00e9s \u00c1, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, H\u00fcttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T (2022) The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33(3):288\u2013298. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"5054_CR79","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d'Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Trumper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M, Committee EG (2015) Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v108-115. https:\/\/doi.org\/10.1093\/annonc\/mdv201","journal-title":"Ann Oncol"},{"key":"5054_CR80","unstructured":"National Comprehensive Cancer Network (NCCN) (2021) Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for T-cell Lymphomas. V.1.2022. \u00a9National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 18, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org . NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"28","key":"5054_CR81","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR (2014) Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol 32(28):3137\u20133143. https:\/\/doi.org\/10.1200\/JCO.2013.54.2456","journal-title":"J Clin Oncol"},{"issue":"10168","key":"5054_CR82","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Huttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trumper L, Group E-S","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Huttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trumper L, Group E-S (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2","journal-title":"Lancet"},{"key":"5054_CR83","unstructured":"ClinicalTrials.gov NCT04569032: A study of brentuximab vedotin and CHP in frontline treatment of PTCL with less than 10% CD30 expression. Seagen, Inc. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569032. Accessed 14 July 2022."},{"key":"5054_CR84","doi-asserted-by":"crossref","unstructured":"Herrera AF, Zain J, Savage KJ, Feldman TA, Brammer JE, Chen L, Popplewell LL, Budde LE, Mei M, Leslie LA, Nair R, Hosin C, Peters L, Forman SJ, Rosen ST, Kwak LW, Iyer SP Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas. In: 63rd ASH Annual Meeting, Georgia, Atlanta, 11\u201314 December 2021.","DOI":"10.1182\/blood-2021-151105"},{"key":"5054_CR85","doi-asserted-by":"crossref","unstructured":"Sibon D, Khater S, Bruneau J, Brouzes C, Lhermitte L, Molina TJ, Cartron G, Morel V, Malamut G, Chauchet A, Morschhauser F, Perard B, Boulet J-M, Gauchy A-C, Cerf-Bensussan N, Macintyre EA, Asnafi V, Cellier C, Hermine O The Eatl-001 trial: results of a phase 2 study of brentuximab vedotin and CHP followed by consolidation with high-dose therapy - autologous stem-cell transplantation (HDT-ASCT) in the frontline treatment of patients with enteropathy-associated T-cell lymphoma. In: 63rd ASH Annual Meeting, Georgia, Atlanta, 11\u201314 December 2021.","DOI":"10.1182\/blood-2021-153709"},{"issue":"26","key":"5054_CR86","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.2020009806","volume":"137","author":"EJ Lowe","year":"2021","unstructured":"Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, Wu R, Alexander S, Bollard CM (2021) Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood 137(26):3595\u20133603. https:\/\/doi.org\/10.1182\/blood.2020009806","journal-title":"Blood"},{"issue":"7","key":"5054_CR87","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1177\/1078155220968615","volume":"27","author":"L Oberic","year":"2021","unstructured":"Oberic L, Delzor F, Protin C, Perriat S, Laurent C, Grand A, Canonge JM, Borel C, Gauthier M, Ysebaert L, Puisset F (2021) Brentuximab vedotin in real life, a seven year experience in patients with refractory\/relapsed CD30+ T cell lymphoma. J Oncol Pharm Pract 27(7):1730\u20131735. https:\/\/doi.org\/10.1177\/1078155220968615","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"5054_CR88","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s12325-021-01764-0","volume":"38","author":"N Martinez-Calle","year":"2021","unstructured":"Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ, Hawkes E, Ahearne MJ, Osborne W, Collins GP, Illidge T, Linton KM, Cwynarski K, Burton C, Fox CP (2021) Systemic ALCL treated in routine clinical practice: outcomes following first-line chemotherapy from a multicentre cohort. Adv Ther 38(7):3789\u20133802. https:\/\/doi.org\/10.1007\/s12325-021-01764-0","journal-title":"Adv Ther"},{"issue":"4","key":"5054_CR89","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ejh.13568","volume":"106","author":"Z Van de Wyngaert","year":"2021","unstructured":"Van de Wyngaert Z, Coppo P, Cervera P, Fabiani B, Lemonnier MP, Corre E, Marjanovic Z, Aoudjhane M, Mohty M, Dulery R (2021) Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed\/refractory peripheral T-cell lymphoma. Eur J Haematol 106(4):467\u2013472. https:\/\/doi.org\/10.1111\/ejh.13568","journal-title":"Eur J Haematol"},{"key":"5054_CR90","doi-asserted-by":"crossref","unstructured":"Bouabdallah K, Aubrais R, Chartier L, Herbaux C, Banos A, Brice P, Ochmann M, Sibon D, Schiano De Colella JM, Cluzeau T, Laribi K, Le Calloch R, Bellal M, Daguindau N, Amorim S, Agbetiafa K, Chauchet A, Hammami M, Durot E, Bonnet C, Robles M, Fouillet L, Bijou F, Tournilhac O, Gaulard P, Parrens M, Milpied N-J, Damaj GL Salvage therapy with brentuximab-vedotin and bendamustine for patients with relapsed\/refractory T cell lymphoma. A multicenter and retrospective study. In: 63rd ASH Annual Meeting, Georgia, Atlanta, 11\u201314 December 2021.","DOI":"10.1182\/bloodadvances.2022008524"},{"issue":"2","key":"5054_CR91","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41417-021-00295-8","volume":"29","author":"Y Wu","year":"2022","unstructured":"Wu Y, Chen D, Lu Y, Dong SC, Ma R, Tang WY, Wu JQ, Feng JF, Wu JZ (2022) A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther 29(2):167\u2013177. https:\/\/doi.org\/10.1038\/s41417-021-00295-8","journal-title":"Cancer Gene Ther"},{"issue":"23","key":"5054_CR92","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","volume":"4","author":"TJ Voorhees","year":"2020","unstructured":"Voorhees TJ, Ghosh N, Grover N, Block J, Cheng C, Morrison K, Ivanova A, Dotti G, Serody J, Savoldo B, Beaven AW (2020) Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy. Blood Adv 4(23):5925\u20135928. https:\/\/doi.org\/10.1182\/bloodadvances.2020003218","journal-title":"Blood Adv"},{"key":"5054_CR93","doi-asserted-by":"publisher","unstructured":"Choe-Juliak C, Alexis KM, Schwarz S, Garcia L, Sawas A (2020) A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: the REDIRECT study design and rationale. J Clin Oncol 38(15_suppl):TPS3148-TPS3148. doi: https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS3148","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3148"},{"key":"5054_CR94","doi-asserted-by":"publisher","unstructured":"Jagadeesh D, Horwitz SM, Bartlett NL, Advani RH, Jacobsen ED, Duvic M, Gautam A, Rao S, Onsum M, Fanale M, Kim YH (2019) Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas. J Clin Oncol 37(15_suppl):7543\u20137543. doi: https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.7543","DOI":"10.1200\/JCO.2019.37.15_suppl.7543"},{"issue":"1","key":"5054_CR95","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bjd.19823","volume":"185","author":"U Wehkamp","year":"2021","unstructured":"Wehkamp U, Mitteldorf C, Stendel S, Stranzenbach R, Nicolay JP, Wobser M, Weichenthal M, Schneiderbauer R, Klemke CD, Hillen U, Kempf W, Assaf C (2021) Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network. Br J Dermatol 185(1):228\u2013230. https:\/\/doi.org\/10.1111\/bjd.19823","journal-title":"Br J Dermatol"},{"issue":"10094","key":"5054_CR96","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dreno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M, Alcanza study group, (2017) Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390(10094):555\u2013566. https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7","journal-title":"Lancet"},{"key":"5054_CR97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","volume":"148","author":"YH Kim","year":"2021","unstructured":"Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R (2021) Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis. Eur J Cancer 148:411\u2013421. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.054","journal-title":"Eur J Cancer"},{"key":"5054_CR98","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","volume":"133","author":"R Dummer","year":"2020","unstructured":"Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M (2020) Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study. Eur J Cancer 133:120\u2013130. https:\/\/doi.org\/10.1016\/j.ejca.2020.04.010","journal-title":"Eur J Cancer"},{"issue":"23","key":"5054_CR99","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","volume":"5","author":"SM Horwitz","year":"2021","unstructured":"Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin LJ, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano JM, Bunn V, Little M, Prince HM (2021) Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data. Blood Adv 5(23):5098\u20135106. https:\/\/doi.org\/10.1182\/bloodadvances.2021004710","journal-title":"Blood Adv"},{"issue":"2","key":"5054_CR100","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/bjd.20786","volume":"186","author":"MH Henderson Berg","year":"2022","unstructured":"Henderson Berg MH, Davison K, Popradi G (2022) Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review. Br J Dermatol 186(2):379\u2013381. https:\/\/doi.org\/10.1111\/bjd.20786","journal-title":"Br J Dermatol"},{"issue":"1","key":"5054_CR101","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4274\/tjh.galenos.2020.2020.0512","volume":"38","author":"M Sahin","year":"2021","unstructured":"Sahin M, Miskioglu M, Inanir I, Akar H, Nese N, Temiz P, Aydogdu I (2021) Cutaneous anaplastic large-cell lymphoma with dramatic response to brentuximab vedotin. Turk J Haematol 38(1):85\u201387. https:\/\/doi.org\/10.4274\/tjh.galenos.2020.2020.0512","journal-title":"Turk J Haematol"},{"issue":"5","key":"5054_CR102","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/bjd.20588","volume":"185","author":"E Papadavid","year":"2021","unstructured":"Papadavid E, Kapniari E, Pappa V, Nikolaou V, Iliakis T, Dalamaga M, Jonak C, Porkert S, Engelina S, Quaglino P, Ortiz-Romero PL, Vico C, Cozzio A, Dimitriou F, Guiron R, Guenova E, Hodak E, Bagot M, Scarisbrick J (2021) Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S\u00e9zary syndrome with variable CD30 positivity. Br J Dermatol 185(5):1035\u20131044. https:\/\/doi.org\/10.1111\/bjd.20588","journal-title":"Br J Dermatol"},{"issue":"6","key":"5054_CR103","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3892\/mco.2021.2283","volume":"14","author":"E Milan","year":"2021","unstructured":"Milan E, Miceli P, Sernicola A, Finotto S, Marino D, Alaibac M (2021) Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin. Mol Clin Oncol 14(6):121. https:\/\/doi.org\/10.3892\/mco.2021.2283","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"5054_CR104","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ddg.14342","volume":"19","author":"R Stranzenbach","year":"2021","unstructured":"Stranzenbach R, Stadler R (2021) Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma. J Dtsch Dermatol Ges 19(3):383\u2013387. https:\/\/doi.org\/10.1111\/ddg.14342","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"5054_CR105","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamadermatol.2020.4901","volume":"157","author":"DJ Lewis","year":"2021","unstructured":"Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ (2021) Brentuximab vedotin for relapsed or refractory S\u00e9zary syndrome. JAMA Dermatol 157(3):317\u2013321. https:\/\/doi.org\/10.1001\/jamadermatol.2020.4901","journal-title":"JAMA Dermatol"},{"issue":"6","key":"5054_CR106","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/ijd.15393","volume":"60","author":"I Lastrucci","year":"2021","unstructured":"Lastrucci I, Grandi V, Gozzini A, Vannucchi M, Kovalchuk S, Santucci M, Pimpinelli N (2021) Complete remission with brentuximab vedotin in a case of primary cutaneous gamma-delta T-cell lymphoma relapsed after allogeneic stem cell transplantation. Int J Dermatol 60(6):778\u2013780. https:\/\/doi.org\/10.1111\/ijd.15393","journal-title":"Int J Dermatol"},{"issue":"1","key":"5054_CR107","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-021-00225-2","volume":"10","author":"S Voruz","year":"2021","unstructured":"Voruz S, de Leval L, Cairoli A (2021) Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine. Exp Hematol Oncol 10(1):32. https:\/\/doi.org\/10.1186\/s40164-021-00225-2","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"5054_CR108","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jaad.2021.07.013","volume":"86","author":"M O'Donnell","year":"2022","unstructured":"O\u2019Donnell M, Zaya R, Correia E, Krishnasamy S, Sahu J, Shi W, Cha J, Alpdogan SO, Porcu P, Nikbakht N (2022) Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: a single-center retrospective study. J Am Acad Dermatol 86(6):1285\u20131292. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.013","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"5054_CR109","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","volume":"106","author":"M Kim","year":"2021","unstructured":"Kim M, Lee JO, Koh J, Kim TM, Lee JY, Jeon YK, Keam B, Kim DW, Lee JS, Heo DS (2021) A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica 106(8):2277\u20132280. https:\/\/doi.org\/10.3324\/haematol.2021.278301","journal-title":"Haematologica"},{"issue":"6","key":"5054_CR110","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/0284186X.2020.1731924","volume":"59","author":"A Kinch","year":"2020","unstructured":"Kinch A, Amini RM, Hollander P, Molin D, Sundstrom C, Enblad G (2020) CD30 expression and survival in posttransplant lymphoproliferative disorders. Acta Oncol 59(6):673\u2013680. https:\/\/doi.org\/10.1080\/0284186X.2020.1731924","journal-title":"Acta Oncol"},{"issue":"16","key":"5054_CR111","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","volume":"129","author":"PL Zinzani","year":"2017","unstructured":"Zinzani PL, Pellegrini C, Chiappella A, Di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V (2017) Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 129(16):2328\u20132330. https:\/\/doi.org\/10.1182\/blood-2017-01-764258","journal-title":"Blood"},{"issue":"33","key":"5054_CR112","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1200\/JCO.19.01492","volume":"37","author":"PL Zinzani","year":"2019","unstructured":"Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ (2019) Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the Phase II CheckMate 436 Study. J Clin Oncol 37(33):3081\u20133089. https:\/\/doi.org\/10.1200\/JCO.19.01492","journal-title":"J Clin Oncol"},{"issue":"6","key":"5054_CR113","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","volume":"106","author":"J Svoboda","year":"2021","unstructured":"Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O\u2019Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ (2021) Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica 106(6):1705\u20131713. https:\/\/doi.org\/10.3324\/haematol.2019.238675","journal-title":"Haematologica"},{"issue":"1","key":"5054_CR114","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/1354750X.2019.1691656","volume":"25","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Climent F, Tapia G, DomingoDomenech E, Mercadal S, Oliveira AC, Aguilera C, Olga G, Moreno Velazquez M, Andrade-Campos M, Encuentra M, Fernandez de Sevilla A, Sureda A, Sancho JM, Gonzalez-Barca E (2020) Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers 25(1):69\u201375. https:\/\/doi.org\/10.1080\/1354750X.2019.1691656","journal-title":"Biomarkers"},{"key":"5054_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.698503","volume":"9","author":"L Lobastova","year":"2021","unstructured":"Lobastova L, Lettau M, Babatz F, de Oliveira TD, Nguyen PH, Pauletti BA, Schauss AC, Durkop H, Janssen O, Paes Leme AF, Hallek M, Hansen HP (2021) CD30-positive extracellular vesicles enable the targeting of CD30-negative DLBCL cells by the CD30 antibody-drug conjugate brentuximab vedotin. Front Cell Dev Biol 9:698503. https:\/\/doi.org\/10.3389\/fcell.2021.698503","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"5054_CR116","doi-asserted-by":"publisher","DOI":"10.12890\/2021_002345","volume":"8","author":"J Ferra","year":"2021","unstructured":"Ferra J, Mousinho F, Miranda F, Andre S, Afonso C, Nogueira F (2021) Use of brentuximab vedotin in a non-HIV patient with primary effusion lymphoma. Eur J Case Rep Intern Med 8(3):002345. https:\/\/doi.org\/10.12890\/2021_002345","journal-title":"Eur J Case Rep Intern Med"},{"issue":"13\u201314","key":"5054_CR117","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/hum.2020.215","volume":"32","author":"S Choi","year":"2021","unstructured":"Choi S, Pegues MA, Lam N, Geldres C, Vanasse D, Kochenderfer JN (2021) Design and assessment of novel anti-CD30 chimeric antigen receptors with human antigen-recognition domains. Hum Gene Ther 32(13\u201314):730\u2013743. https:\/\/doi.org\/10.1089\/hum.2020.215","journal-title":"Hum Gene Ther"},{"issue":"4","key":"5054_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1268","volume":"10","author":"C Alvarez-Fernandez","year":"2021","unstructured":"Alvarez-Fernandez C, Escriba-Garcia L, Caballero AC, Escudero-Lopez E, Ujaldon-Miro C, Montserrat-Torres R, Pujol-Fernandez P, Sierra J, Briones J (2021) Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Clin Transl Immunology 10(4):e1268. https:\/\/doi.org\/10.1002\/cti2.1268","journal-title":"Clin Transl Immunology"},{"issue":"13","key":"5054_CR119","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED (2019) Polatuzumab vedotin: first global approval. Drugs 79(13):1467\u20131475. https:\/\/doi.org\/10.1007\/s40265-019-01175-0","journal-title":"Drugs"},{"issue":"6","key":"5054_CR120","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","volume":"8","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S (2021) Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol 8(6):e433\u2013e445. https:\/\/doi.org\/10.1016\/S2352-3026(21)00103-4","journal-title":"Lancet Haematol"},{"issue":"3","key":"5054_CR121","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1021\/acs.bioconjchem.1c00058","volume":"32","author":"L Juen","year":"2021","unstructured":"Juen L, Baltus CB, Gely C, Feuillatre O, Desgranges A, Viaud-Massuard MC, Martin C (2021) Innovative bioconjugation technology for antibody-drug conjugates: proof of concept in a CD30-positive lymphoma mouse model. Bioconjug Chem 32(3):595\u2013606. https:\/\/doi.org\/10.1021\/acs.bioconjchem.1c00058","journal-title":"Bioconjug Chem"},{"issue":"2","key":"5054_CR122","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","volume":"58","author":"K Karube","year":"2008","unstructured":"Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Sugita Y, Ohshima K (2008) Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int 58(2):89\u201397. https:\/\/doi.org\/10.1111\/j.1440-1827.2007.02195.x","journal-title":"Pathol Int"},{"issue":"12","key":"5054_CR123","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rudiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM, International Peripheral TcLP","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rudiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM, International Peripheral TcLP (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117(12):3402\u20133408. https:\/\/doi.org\/10.1182\/blood-2010-09-310342","journal-title":"Blood"},{"issue":"8","key":"5054_CR124","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, Zinzani PL, Pileri SA (2013) CD30 expression in peripheral T-cell lymphomas. Haematologica 98(8):e81-82. https:\/\/doi.org\/10.3324\/haematol.2013.084913","journal-title":"Haematologica"},{"issue":"19","key":"5054_CR125","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","volume":"124","author":"C Bossard","year":"2014","unstructured":"Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, Martin A, Fabiani B, Delarue R, Tournilhac O, Delorenzi M, Gaulard P, de Leval L (2014) Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood 124(19):2983\u20132986. https:\/\/doi.org\/10.1182\/blood-2014-07-584953","journal-title":"Blood"},{"issue":"3","key":"5054_CR126","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","volume":"101","author":"M Lamarque","year":"2016","unstructured":"Lamarque M, Bossard C, Contejean A, Brice P, Parrens M, Le Gouill S, Briere J, Bouabdallah R, Canioni D, Tilly H, Bouchindhomme B, Bachy E, Delarue R, Haioun C, Gaulard P (2016) Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica 101(3):e103-106. https:\/\/doi.org\/10.3324\/haematol.2015.135400","journal-title":"Haematologica"},{"issue":"1","key":"5054_CR127","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/hon.2482","volume":"36","author":"K Kawamoto","year":"2018","unstructured":"Kawamoto K, Miyoshi H, Suzuki T, Sasaki Y, Yamada K, Yanagida E, Muto R, Kiryu M, Sone H, Seto M, Ohshima K, Takizawa J (2018) Frequent expression of CD30 in extranodal NK\/T-cell lymphoma: potential therapeutic target for anti-CD30 antibody-based therapy. Hematol Oncol 36(1):166\u2013173. https:\/\/doi.org\/10.1002\/hon.2482","journal-title":"Hematol Oncol"},{"issue":"3","key":"5054_CR128","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3892\/ol.2017.5592","volume":"13","author":"GN Wang","year":"2017","unstructured":"Wang GN, Zhao WG, Li L, Zhang DD, Gao XZ, Zhou J, Zhang L, Fu XR, Zheng XY, Li Y, Li Z, Zhang MZ, Li WC (2017) Prognostic significance of CD30 expression in nasal natural killer\/T-cell lymphoma. Oncol Lett 13(3):1211\u20131215. https:\/\/doi.org\/10.3892\/ol.2017.5592","journal-title":"Oncol Lett"},{"issue":"7","key":"5054_CR129","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","volume":"119","author":"MF Benner","year":"2012","unstructured":"Benner MF, Jansen PM, Vermeer MH, Willemze R (2012) Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 119(7):1643\u20131649. https:\/\/doi.org\/10.1182\/blood-2011-08-376319","journal-title":"Blood"},{"issue":"1","key":"5054_CR130","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjd.13832","volume":"173","author":"CD Klemke","year":"2015","unstructured":"Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, Geraud C, Kempf W, Assaf C, Ortonne N, Battistella M, Bagot M, Knobler R, Quaglino P, Arheiliger B, Santucci M, Jansen P, Vermeer MH, Willemze R (2015) Histopathological and immunophenotypical criteria for the diagnosis of S\u00e9zary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol 173(1):93\u2013105. https:\/\/doi.org\/10.1111\/bjd.13832","journal-title":"Br J Dermatol"},{"issue":"5","key":"5054_CR131","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/bjh.13085","volume":"167","author":"GW Slack","year":"2014","unstructured":"Slack GW, Steidl C, Sehn LH, Gascoyne RD (2014) CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol 167(5):608\u2013617. https:\/\/doi.org\/10.1111\/bjh.13085","journal-title":"Br J Haematol"},{"issue":"14","key":"5054_CR132","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Moller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715\u20132724. https:\/\/doi.org\/10.1182\/blood-2012-10-461848","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05054-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T04:05:19Z","timestamp":1682481919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5054"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05054-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"HMP has received honoraria from Takeda, Mundi Pharma, and Bristol Myers Squibb. MH has received honoraria from Genmab, Roche, and Takeda. EDD has received honoraria from Takeda and Bristol Myers Squibb. DAE has received honoraria from Sanofi-Genzyme and Takeda. RA has received honoraria from Roche, Bristol Myers Squibb, Incyte, Epizyme, Karyopharm Merck, Daiichi, and ADCT.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}